Nkarta, Inc.
NKTX
Rank in Stocks
#19127
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and... Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Share Price
$1.59
Last synced: 2026-11-09
Market Cap
$113.88M
Change (1 day)
-8.09%
Change (1 year)
-20.90%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nkarta, Inc. (NKTX)
Category
Healthcare
Operating Margin for Nkarta, Inc. (NKTX)
Operating Margin as of November 2026 TTM: 0.00%
According to Nkarta, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Nkarta, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | -100.00% |
| 2019 | -19,368.66% | 355,941.54% |
| 2018 | -5.44% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Nkarta, Inc.'s operating margin
What was Nkarta, Inc.'s operating margin in 2025?
In 2025, Nkarta, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has Nkarta, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Nkarta, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2025 (0.00%).
How does Nkarta, Inc.'s operating margin compare with similar companies?
Nkarta, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.